Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Background: Antipsychotics modulate expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to treat SARS-CoV-2 infection in a repurposing study. We aim to investigate the po...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Pharmacol
Päätekijät: Crespo-Facorro, Benedicto, Ruiz-Veguilla, Miguel, Vázquez-Bourgon, Javier, Sánchez-Hidalgo, Ana C., Garrido-Torres, Nathalia, Cisneros, Jose M., Prieto, Carlos, Sainz, Jesus
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2021
Aiheet:
Pharmacology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7982825/
https://ncbi.nlm.nih.gov/pubmed/33762960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.646701
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia